Ensign Peak Advisors, Inc Pacira Bio Sciences, Inc. Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 21,020 shares of PCRX stock, worth $524,869. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,020
Previous 21,020
-0.0%
Holding current value
$524,869
Previous $316,000
25.32%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PCRX
# of Institutions
259Shares Held
49.3MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$200 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$131 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$81.5 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.4 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$49.8 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...